The US Food and Drug Administration has conveyed its desire to see future new drug applications for opioids demonstrate a comparative advantage over existing analgesics, and the agency is getting some public support from sponsors.
Although companies commenting on the FDA's June 2019 draft guidance on the benefit/risk assessment framework for opioids raised a variety of issues they would like to see addressed in the final guidance, several gave the agency the thumbs up for seeking active comparator data